arGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies

20-May-2015 - Netherlands

arGEN-X N.V. announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). This grant will be used to advance and commercialize the application of the NHance® Fc modifications in therapeutic antibodies.
 
“We are very pleased to have received this support from IWT. As an organization, IWT has enabled the steady build of highly competitive Flemish biotechnology companies and we hope to continue this reputation with the advancement of our own novel, cutting edge research. NHance® is our proprietary approach to prolonging antibody circulation time. With the IWT grant, we aim to further confirm the benefit of antibodies equipped with NHance® by demonstrating enhanced tissue and tumor penetration with select antibody candidates in murine disease models,” commented Michael Saunders, Senior Director, Targets & Programs at arGEN-X. “In addition, efficient sweeping of the disease target by Fc modified antibodies can be further explored as NHance® has the game changing benefit of enhanced clearance of the target while the recycled antibody can be used for renewed target binding.”

Other news from the department science

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous